Literature DB >> 8640316

[Residual risks of viral transmission by transfusions and projected yields of additional screening tests. Retrovirus Epidemiology Donors Study (REDS)].

M P Busch1.   

Abstract

The residual risk of virus transmission associated with infectious seroconversion, window period donations can be estimated by combining the incidence rate of infection among repeat donors with the duration of the pre-seroconversion window period, thus deriving the rate of window phase donations missed by current screening. The residual risks are for HIV 2.0/10(6); HTLV 1.6/10(6); HCV 9.7/10(6); HBV 15.0/10(6). Similarly the net yield and incremental reduction in risk of routine implementation of new tests can be estimated, demonstrating the potential interest of nucleic acid detection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640316     DOI: 10.1016/s1246-7820(96)80007-3

Source DB:  PubMed          Journal:  Transfus Clin Biol        ISSN: 1246-7820            Impact factor:   1.406


  3 in total

1.  Incidence and Residual Risk of HIV, HBV and HCV Infections Among Blood Donors in Tehran.

Authors:  Hamid Reza Saber; Seyed Morteza Tabatabaee; Ali Abasian; Mostafa Jamali; Ebadollah SalekMoghadam; Bashir Hajibeigi; Seyed Moayed Alavian; Seyed Mohammad Mirrezaie
Journal:  Indian J Hematol Blood Transfus       Date:  2016-10-01       Impact factor: 0.900

2.  10-year analysis of human immunodeficiency virus incidence in first-time and repeat donors in Brazil.

Authors:  Sheila de Oliveira Garcia Mateos; Liliana Preiss; Thelma T Gonçalez; Claudia Di Lorenzo Oliveira; Eduard Grebe; Clara Di Germanio; Mars Stone; Luiz Amorim Filho; Anna Bárbara Carneiro Proietti; Andre Rolim Belisario; Cesar de Almeida-Neto; Alfredo Mendrone-Junior; Paula Loureiro; Michael P Busch; Brian Custer; Ester Cerdeira Sabino
Journal:  Vox Sang       Date:  2020-09-30       Impact factor: 2.144

3.  CCR2-64I polymorphism is not associated with altered CCR5 expression or coreceptor function.

Authors:  R Mariani; S Wong; L C Mulder; D A Wilkinson; A L Reinhart; G LaRosa; R Nibbs; T R O'Brien; N L Michael; R I Connor; M Macdonald; M Busch; R A Koup; N R Landau
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.